Loading
A phase 1/2 trial of ISM6331 in mesothelioma, run by InSilico Medicine Hong Kong Limited, now recruiting.
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06566079 by InSilico Medicine Hong Kong Limited, with 160 participants planned, started 2024-12-27 and due to reach its primary completion in 2027-08-31. Interventions recorded: ISM6331.
Shares Insilico Medicine and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.